SpaceX vs. Rocket Lab: Which Is the Better Space Stock to Buy Right Now?

Rocket Lab appears favored: Q1 revenue rose 64% to $200M and losses narrowed to -$0.07/share (from -$0.12). SpaceX’s Q1 loss widened sharply to -$3.29/share (from -$0.41 y/y) as capital expenditures surged to $10B in Q1 2026 (vs $27B for all of 2025), despite sales increasing 15% to $4.7B. Valuation is a key contrast (SpaceX P/S ~94 vs Rocket Lab ~66), with the article arguing Rocket Lab’s better risk/reward makes it the better buy, though both stocks are described as volatile.

Analysis

The important market read-through is that capital intensity is now the real gatekeeper in space, not launch headlines. When a private leader is forcing more and more dollars into build-out, public comps tend to get re-rated from TAM stories to funding-risk stories; that is bearish for any high-multiple space equity that still needs years of operating leverage to justify today’s price. RKLB is the cleaner public vehicle only if it can keep converting launch cadence into recurring cash flow, because the market will eventually stop rewarding backlog unless margin and free cash flow move with it.

The second-order effect is that recurring communications assets are becoming more valuable than pure launch exposure. IRDM’s subscriber base and profitability matter more than they look on the surface because the scarce asset is sticky, cash-generative connectivity, while launch remains a cyclical service business with lumpy utilization. If RKLB absorbs IRDM, the bull case shifts from "more launches" to "better blended cash flows," but that also introduces financing, integration, and leverage risk over the next 3-12 months.

Contrarian view: the consensus is probably overemphasizing launch share gains and underweighting balance-sheet and dilution sensitivity. The biggest falsifier for a bullish RKLB thesis is not one weak quarter; it is any sign that launch volume is improving faster than gross margin and operating cash burn, or that the Iridium deal terms require more equity than the market expects. If that happens, the public market may reprice RKLB as a capital-hungry consolidator rather than a category winner.

Key Decisions for Investors

• Keep RKLB on a tactical buy list only on weakness, not at an elevated multiple; the thesis needs continued launch cadence plus visible margin improvement over the next 1-2 quarters. Falsify if revenue growth persists but EBITDA/FCF burn does not narrow.
• Set a merger-arb alert on IRDM: if the implied deal spread widens materially without new financing or regulatory issues, long IRDM / short RKLB becomes the cleaner relative-value expression over the next 3-6 months. Pass if the spread is already tight or if consideration is meaningfully stock-heavy and leverages RKLB further.
• Avoid chasing space baskets purely on the SpaceX narrative; the public-market beneficiary is not the private leader but whichever company can prove recurring cash flow. Use IRDM as the quality screen and treat any launch-only name as higher-risk beta.
• If RKLB reports another quarter of revenue acceleration but no improvement in free cash flow conversion, fade strength with a small short or call-spread sell against strength; the market is likely ahead of fundamentals. Cover if management raises full-year margin or cash burn guidance.
• Watch for any disclosure on deal financing, regulatory timing, or integration costs around IRDM: those are the next 1-3 month catalysts that can swing the stock more than launch contract announcements.